Multimodality evaluation of transcatheter structural valve degeneration at long-term follow-up.

Degeneración estructural de la válvula Ecocardiografía transesofágica Implante percutáneo de válvula aórtica Long-term follow-up Seguimiento a largo plazo Structural valve degeneration Tomografía computarizada con multidetectores Transcatheter aortic valve replacement Transesophageal echocardiography Multidetector computed tomography

Journal

Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 17 09 2019
accepted: 20 01 2020
pubmed: 13 4 2020
medline: 23 4 2021
entrez: 13 4 2020
Statut: ppublish

Résumé

We assessed the long-term hemodynamic performance of transcatheter heart valve (THV) by paired transthoracic echocardiography (TTE), and the incidence, characteristics and factors associated with THV structural valve degeneration (SVD). A total of 212 patients who underwent transcatheter aortic valve replacement and had a potential follow-up >5 years with at least 1 TTE ≥ 1-year postprocedure were included. All patients had a TTE at 1 to 5 years and 36 had another one at 6 to 10 years. SVD was defined as subclinical (increase >10mmHg in mean transvalvular gradient+decrease >0.3cm Transvalvular mean gradient increased and valve area decreased over time (P<.01). At 8 years of follow-up, SVD occurred in 30.2% of patients (clinically relevant: 9.3%). Transesophageal echocardiography revealed thickened and reduced-mobility leaflets in 80% and 73% of SVD cases, respectively. No baseline or procedural factors were associated with SVD. THV underexpansion (3.5%) or eccentricity (8.2%) had no impact on valve hemodynamics/SVD at follow-up. A gradual THV hemodynamic deterioration occurred throughout a 10-year period, leading to SVD in ∼30% of patients (clinically relevant in < 10%). Leaflet morphology/mobility were frequently impaired in SVD cases, but THV geometry did not influence valve hemodynamics or SVD.

Identifiants

pubmed: 32278660
pii: S1885-5857(20)30043-8
doi: 10.1016/j.rec.2020.02.002
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

247-256

Informations de copyright

Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Alfredo Nunes Ferreira-Neto (AN)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Tania Rodriguez-Gabella (T)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Leonardo Guimaraes (L)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Afonso Freitas-Ferraz (A)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Mathieu Bernier (M)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Camila Figueiredo Guimaraes (C)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Sergio Pasian (S)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Jean-Michel Paradis (JM)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Robert Delarochellière (R)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Eric Dumont (E)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Siamak Mohammadi (S)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Dimitri Kalavrouziotis (D)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Mélanie Côté (M)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Philippe Pibarot (P)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH